Lv3
290 积分 2024-05-08 加入
De-escalation trials in multiple myeloma: past, present and future
4小时前
已完结
Prognostic significance of dynamic minimal residual disease trajectories in newly diagnosed multiple myeloma
17天前
已完结
Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial
1个月前
已完结
Rapidly Progressive Alzheimer Disease and Related Dementias as a Phase Transition: Symptom Cascades and Survival Inflection
1个月前
已完结
Concurrent antiviral-immunochemotherapy strategy safely overcomes high hepatitis B viral load barrier in diffuse large B-cell lymphoma: A multicentre cohort study
1个月前
已完结
Modeling MRD Changes in Myeloma to Understand Treatment Effects, Predict Outcomes, and Investigate Curative Potential
2个月前
已完结
Measurable residual disease in hematologic malignancies: a biomarker in search of a standard
2个月前
已完结
Minimal residual disease and imaging‐guided consolidation strategies in newly diagnosed and relapsed refractory multiple myeloma
2个月前
已完结
Measurable Residual Disease–Guided Therapy in Newly Diagnosed Myeloma
2个月前
已完结
MRD in multiple myeloma: From an early endpoint for accelerated approval to MRD driven treatment and clinical management
2个月前
已完结
皖公网安备34019202002308
